Aquamal QS x 6 Tablets
Manufactured By Pinnacle Health Pharmaceutical Limited
Composition Artemether 80mg & Lumefantrine 480mg
Includes all taxes
( 1 Pack of 6 Tablets )
Aquamal QS comprises a fixed combination of 1 part of Artemether and 6 parts of Lumefantrine. Artemether has quick onset of action while Lumefantrine has longer duration of action. Both exerts their anti-parasitic action at the blood stage of malarial parasite, where they convert the haem (a toxic metabolite produced during haemoglobin breakdown) to nontoxic haemozoin (malaria pigment).
Lumefantrine interfaces with the polymerization process, while Artemether generates reactive metabolites as a result of interaction between its peroxide bridge & haem iron. Both components also have a secondary action involving inhibition of nucleic acid and protein synthesis within the malarial parasite. There is a synergism of independant actions of both Artemether and Lumefantrine, which has been shown to potentiate the blood schizontocidal effects.
It is also effective against drug resistant strains of P. falciparum malaria.
Uses / Indications: Artemether / Lumefantrine is indicated for the treatment of uncomplicated P. falciparum malaria including multi-drug resistant strains of P. falciparum. Aquamal QS is also effective against the blood stage of P. vivax but not active against hypnozoites. Artemether / Lumefantrine must be used for the malaria infections acquired in areas where the parasites may be resistant to other anti-malarial drugs. World Health Organization recommends Artemether / Lumefantrine as a first line treatment for the acute uncomplicated P. falciparum malaria for both multi-drug resistant areas & drug sensitive areas.
- Product composition:
- Artemether 80mg & Lumefantrine 480mg
Artemether / Lumefantrine is contra-indicated to those patients which have a history of hypersensitivity to Artemether / Lumefantrine
- Pregnancy interaction:
- Pregnancy: There are no adequate data from the use of Artemether / Lumefantrine in pregnant women. Artemether / Lumefantrine treatment should only be considered if the expected benefit to the mother outweighs the risk to the fetus Lactation: Artemether / Lumefantrine excretes into breast milk. It should not be taken by breast-feeding women
- Side Effects:
- Artemether / Lumefantrine is well tolerated and there is no drug induced serious unwanted side effects. The most common adverse experiences (> 1%) in patients treated with Artemether / Lumefantrine combination are abdominal pain, diarrhoea, vomiting, nausea, palpitation, headache, dizziness, arthralgia, cough, myalgia, pruritis, rash, asthenia and fatigue
- How to use:
- Patients with acute malaria are frequently averse to food. The dose may be encouraged to resume normal eating as soon as food can be tolerated since this improves absorption of Artemether and Lumefantrine. In the event of vomiting within 1 hour of administration a repeat dose should be taken. 6-dose regimen should be given over 3 days. First dose at the time of initial diagnosis and then at 8, 24, 36, 48 & 60 hrs
- Medicine interaction:
- Patients who are taking any drug which inhibits the cytochrome enzyme CYP3A4 (e.g. erythromycin, ketoconazole, itraconazole, cimetidine, HIV protease inhibitor, etc.) Patients who are taking any drug which is metabolized by the cytochrome enzyme CYP2D6 (e.g. flecainide, metoprolol, imipramine, amitryptyline, clomipramine etc.)